NO20062361L - Bakterielle virulens faktorer og anvendelser derav - Google Patents

Bakterielle virulens faktorer og anvendelser derav

Info

Publication number
NO20062361L
NO20062361L NO20062361A NO20062361A NO20062361L NO 20062361 L NO20062361 L NO 20062361L NO 20062361 A NO20062361 A NO 20062361A NO 20062361 A NO20062361 A NO 20062361A NO 20062361 L NO20062361 L NO 20062361L
Authority
NO
Norway
Prior art keywords
virulence factors
bacterial virulence
polypeptides
secreted proteins
pathogens
Prior art date
Application number
NO20062361A
Other languages
English (en)
Norwegian (no)
Inventor
Brett Finlay
Samantha Gruenheid
Wanyin Deng
Bruce Vallance
Jose L Puente
Original Assignee
Univ Mexico Nacional Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mexico Nacional Autonoma filed Critical Univ Mexico Nacional Autonoma
Publication of NO20062361L publication Critical patent/NO20062361L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
NO20062361A 2003-10-31 2006-05-23 Bakterielle virulens faktorer og anvendelser derav NO20062361L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51570303P 2003-10-31 2003-10-31
PCT/CA2004/001891 WO2005042746A1 (en) 2003-10-31 2004-10-29 Bacterial virulence factors and uses thereof

Publications (1)

Publication Number Publication Date
NO20062361L true NO20062361L (no) 2006-07-20

Family

ID=34549436

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062361A NO20062361L (no) 2003-10-31 2006-05-23 Bakterielle virulens faktorer og anvendelser derav

Country Status (16)

Country Link
US (2) US8758771B2 (pt)
EP (3) EP2462948A1 (pt)
JP (2) JP5100122B2 (pt)
KR (3) KR20130018999A (pt)
CN (2) CN1922324B (pt)
AR (1) AR050050A1 (pt)
AU (2) AU2004286002B2 (pt)
BR (1) BRPI0415816A (pt)
CA (1) CA2543763A1 (pt)
MX (1) MXPA06004858A (pt)
NO (1) NO20062361L (pt)
NZ (1) NZ547156A (pt)
RU (2) RU2465331C2 (pt)
UA (1) UA94206C2 (pt)
WO (1) WO2005042746A1 (pt)
ZA (1) ZA200604412B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06004858A (es) 2003-10-31 2007-04-16 Univ British Columbia Factores de virulencia bacteriana y sus usos.
US9107864B2 (en) * 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
EP1815016B1 (en) * 2004-11-01 2012-06-27 George Mason University Compositions and methods for diagnosing colon disorders
AU2007247869B2 (en) * 2006-05-05 2013-11-21 Opexa Therapeutics T-cell vaccine
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
GB0909198D0 (en) * 2009-05-28 2009-07-15 Queen Mary & Westfield College Methods and composition for treating NF-kappa B mediated disorders
WO2011005587A1 (en) * 2009-06-24 2011-01-13 University Of Dubuque Vaccine compositions and methods of use to protect against infectious disease
WO2011007350A2 (en) * 2009-07-13 2011-01-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Immunomodulatory agents and a tissue-targeted delivery system thereof for the treatment of immune-related disorders
EP2292799A1 (en) 2009-08-11 2011-03-09 Agence Française de Securité Sanitaire des Aliments An assay for determining a molecular risk assessment of stec isolates
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
EP2620156B1 (en) 2010-08-23 2019-03-27 Kang Stem Biotech Co., Ltd. Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing stem cells treated with nod2 agonist or cultured product thereof
RU2497541C1 (ru) * 2012-07-20 2013-11-10 федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почётного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Фармацевтическая композиция на основе лигандов паттерн-распознающих рецепторов, способ ее использования в качестве иммуностимулятора для лечения инфекций, вызванных бактериальными и вирусными патогенами, способ ее использования в качестве адъюванта в составе вакцин
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9579370B2 (en) 2014-03-04 2017-02-28 The Board Of Regents Of The University Of Texas System Compositions and methods for enterohemorrhagic Escherichia coli (EHEC)vaccination
US10226520B2 (en) 2014-03-04 2019-03-12 The Board Of Regents Of The University Of Texa System Compositions and methods for enterohemorrhagic Escherichia coli (EHEC) vaccination
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN109206484B (zh) * 2015-11-20 2021-06-18 深圳市南山区人民医院 一种用于预防和治疗肠致病大肠杆菌感染的肽段
CN105821065A (zh) * 2016-04-29 2016-08-03 南方医科大学 一种双抗原重组蛋白及其制备方法和应用
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2019147988A1 (en) * 2018-01-25 2019-08-01 Innate Biologics Llc Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents
CN111788315A (zh) * 2018-03-29 2020-10-16 金伯利-克拉克环球有限公司 用于指示潜在的即将出现的皮肤或胃肠道问题的传感器及其使用方法
EP3962512A4 (en) * 2019-05-01 2023-01-18 Innate Biologics LLC IMMUNOMODULATORY COMPOSITIONS AND METHODS
CN113174389B (zh) * 2021-05-27 2023-06-16 昆明理工大学 一种岷江百合诱导型启动子pr4及其应用
CN118910018B (zh) * 2024-07-31 2025-03-21 徐州医科大学 一种利用位点指引的突变形成技术增强NleC蛋白稳定性的优化方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310550A (en) 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US5151267A (en) 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
SE9100556D0 (sv) * 1991-02-26 1991-02-26 Holmgren Jan Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans
US5370989A (en) * 1992-04-03 1994-12-06 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
RU2043771C1 (ru) * 1993-02-25 1995-09-20 Михаил Константинович Пирожков Вакцина против эшерихиоза животных
US5951988A (en) 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
DE69426051T2 (de) 1993-07-30 2001-05-10 Akzo Nobel N.V., Arnheim/Arnhem Impfstoff für Geflügel
WO1996040861A1 (en) 1995-06-07 1996-12-19 Biolog, Inc. Microbiological media for isolation and identification of enteric pathogens such as e. coli and salmonella
FR2747394B1 (fr) 1996-04-15 1998-07-03 Rambach Alain Milieu de culture pour la mise en evidence des bacteries e. coli enterohemorragiques, et procede pour sa mise en evidence
EP0904288B1 (en) 1996-04-23 2012-06-13 The University Of British Columbia Vaccine comprising the pathogenic escherichia coli associated protein espa
DE69842019D1 (de) 1997-10-16 2011-01-05 Synageva Biopharma Corp Transgene vögel und proteinproduktion
US7208574B1 (en) 1997-11-12 2007-04-24 The University Of British Columbia Host receptor for pathogenic bacteria
AU1137399A (en) 1997-11-12 1999-05-31 University Of British Columbia, The Hp90: host membrane receptor for pathogenic bacteria, encoded by the bacterial tir gene
US6365723B1 (en) * 1998-12-04 2002-04-02 Wisconsin Alumni Research Foundation Sequences of E. coli O157
US20020132788A1 (en) 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
BR0206312A (pt) 2001-01-04 2004-02-17 Univ Saskatchewan Composição de vacina, uso sobrenadante de cultura celular de escherichia coli enteroemorrágica (ehec), e, métodos para a geração de uma resposta imunológica em um mamìfero contra um antìgeno de escherichia coli enteroemorrágica (ehec) secretado, e 0157:h7 enteroemorrágica (ehec 0157:h7) secretado, e para a redução da colonização de escherichia coli enteroemorrágica (ehec) em um ruminante
JP2002355074A (ja) 2001-01-24 2002-12-10 Univ Tsukuba 腸管出血性病原性大腸菌ｏ１５７：ｈ７に特異的な核酸分子およびポリペプチド並びにこれらの使用方法
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
MXPA06004858A (es) 2003-10-31 2007-04-16 Univ British Columbia Factores de virulencia bacteriana y sus usos.

Also Published As

Publication number Publication date
NZ547156A (en) 2009-08-28
ZA200604412B (en) 2007-09-26
CN101711861A (zh) 2010-05-26
RU2006118803A (ru) 2007-12-10
JP5100122B2 (ja) 2012-12-19
CN1922324A (zh) 2007-02-28
EP2462948A1 (en) 2012-06-13
RU2012122559A (ru) 2013-12-10
CA2543763A1 (en) 2005-05-12
CN1922324B (zh) 2010-06-09
AU2011201889A1 (en) 2011-05-19
US20070041997A1 (en) 2007-02-22
BRPI0415816A (pt) 2006-12-26
KR20130018999A (ko) 2013-02-25
AU2004286002A1 (en) 2005-05-12
EP1692287A1 (en) 2006-08-23
WO2005042746A1 (en) 2005-05-12
JP2007531511A (ja) 2007-11-08
EP1692287A4 (en) 2007-03-28
AU2004286002B2 (en) 2011-01-27
MXPA06004858A (es) 2007-04-16
EP2383287A1 (en) 2011-11-02
UA94206C2 (ru) 2011-04-26
US8758771B2 (en) 2014-06-24
KR20110102956A (ko) 2011-09-19
AR050050A1 (es) 2006-09-27
US8507249B2 (en) 2013-08-13
JP2011250790A (ja) 2011-12-15
KR20070031848A (ko) 2007-03-20
KR101242445B1 (ko) 2013-03-15
RU2465331C2 (ru) 2012-10-27
US20120064572A1 (en) 2012-03-15
AU2011201889B2 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
NO20062361L (no) Bakterielle virulens faktorer og anvendelser derav
Argemi et al. Is Staphylococcus lugdunensis significant in clinical samples?
Soheili et al. Wide distribution of virulence genes among Enterococcus faecium and Enterococcus faecalis clinical isolates
Ronci et al. Identification and characterization of the α-CA in the outer membrane vesicles produced by Helicobacter pylori
NO20083153L (no) Kjemiske forbindelser
DE602004026077D1 (de) Erstellung von expressionsprofilen unter verwendung von mikroarrays
Ordinola‐Zapata et al. The root canal microbiome diversity and function. A whole‐metagenome shotgun analysis
Zheng et al. Distinct biological potential of Streptococcus gordonii and Streptococcus sanguinis revealed by comparative genome analysis
EP2290067A3 (en) Methods and compositions involving microRNA
BRPI0414722A (pt) meios sem produto animal e processos para obtenção de uma toxina botulìnica
EA201301072A1 (ru) Антитела против il-23p19 и их применение
ATE517194T1 (de) Zusammensetzungen zur verwendung bei der bestimmung von hämorrhagischen fieberviren
NO20081013L (no) 7-substituerte aza-indazoler, sammensetninger inneholdende disse, produksjonsmetode og anvendelse derav
ATE330038T1 (de) Nukleinsäure-biosensor
ATE494588T1 (de) Verfahren zur mikrorna-identifikation und ihrer anwendungen bei der forschung und menschlichen gesundheit
Duncan Genomics of oral bacteria
Ho et al. Identification of Streptococcus cristatus peptides that repress expression of virulence genes in Porphyromonas gingivalis
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
BRPI0508064A (pt) flavivìrus, composição de vacina e molécula de ácido nucléico
Lo et al. Distribution of virulence factors and association with emm polymorphism or isolation site among beta‐hemolytic group G Streptococcus dysgalactiae subspecies equisimilis
ATE466079T1 (de) Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs
Romeo et al. Genetic Diversity, Biofilm Formation, and Antibiotic Resistance in Listeria monocytogenes Isolated from Meat-Processing Plants
Mosiej et al. Multi-locus variable-number tandem repeat analysis of Bordetella pertussis isolates circulating in Poland in the period 1959–2013
Lapirattanakul et al. Multilocus sequence typing analysis of Streptococcus mutans strains with the cnm gene encoding collagen-binding adhesin
NO20064715L (no) Deteksjon, isolering og anvendelse av renalase (monoamin aksidase C)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application